ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company (“Ordinary Shares”) at a price of 144p per share (the “Placing…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment. Final patient data from the trial are…